Objective: Adjuvant radiotherapy for head and neck cancer patient management continues to be paralleled with costly and devastating bone related pathologies. Most detrimental is the development of non-unions secondary to pathologic fractures. A pharmacologic means to prevent these pathologies would be highly desirable. Deferoxamine (DFO), an angiogenic therapy, augments vascularity and subsequently enhances fracture healing when injected into a fracture callus. We posit that the untoward effects of radiotherapy on bone quality, mechanical strength and non-union formation can be mitigated with this powerful angiogenic therapy.
